Skip to main content
Clinical Trials/NCT02214732
NCT02214732
Completed
Not Applicable

A Randomized Controlled Trial of Mindfulness Based Cognitive Therapy for Psychological Distress in Pregnancy

University of Calgary2 sites in 1 country61 target enrollmentAugust 2014

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Depression
Sponsor
University of Calgary
Enrollment
61
Locations
2
Primary Endpoint
Change in Edinburgh Postpartum Depression Scale scores from baseline to 3 months follow-up postpartum
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

Anxiety, stress and depression are common during pregnancy and in the postpartum period. The lack of empirically supported, non-pharmaceutical interventions for psychological distress in pregnancy is a significant gap in the literature, especially given many pregnant women's preference for non-pharmaceutical treatments. This study will evaluate the efficacy of Mindfulness Based Cognitive Therapy (MBCT) program in reducing measures of psychological distress (e.g., symptoms of stress, depression and anxiety) in a group of pregnant women endorsing high levels of distress.

Registry
clinicaltrials.gov
Start Date
August 2014
End Date
September 2017
Last Updated
7 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Lianne Tomfohr-Madsen

Assistant Professor of Psychology

University of Calgary

Eligibility Criteria

Inclusion Criteria

  • Eligible women for this study
  • are between 12 and 28 weeks of gestation,
  • are experiencing psychological distress (elevated perinatal anxiety, mild depressive symptoms, or high-levels of self-reported stress)

Exclusion Criteria

  • current suicidality
  • current substance abuse or dependence
  • experience a current major depressive episode
  • have been diagnosed with bipolar disorder or other disorders that have a psychotic, dissociative, hallucinatory, or delusional component
  • taking prescribed medications that affect sleep or mood

Outcomes

Primary Outcomes

Change in Edinburgh Postpartum Depression Scale scores from baseline to 3 months follow-up postpartum

Time Frame: Baseline (Week 1), Post-Treatment (Week 10), 3 months follow-up postpartum (3 months after the birth of a person's baby)

Symptoms of depression will be assessed using the 10-item, self-report Edinburgh Postpartum Depression Scale (EPDS). The EPDS has been validated against interview schedules and other self-report instruments.

Secondary Outcomes

  • Change in Perceived Stress Scale (PSS-10) scores from baseline to 3 months(Baseline (Week 1), Post-Treatment (Week 10), 3 months follow-up postpartum)
  • Change in measures of blood pressure (BP) from baseline to 3 months(Baseline (Week 1), Post-Treatment (Week 10), 3 months follow-up postpartum)
  • Change in objective measures of sleep using Wrist Actigraphy from baseline to 3 months(Baseline (Week 1), Post-Treatment (Week 10), 3 months follow-up postpartum)
  • Change in Pittsburgh Sleep Quality Index (PSQI) scores from baseline to 3 months(Baseline (Week 1), Post-Treatment (Week 10), 3 months follow-up postpartum)
  • Change in salivary cortisol profile from baseline to 3 months(Baseline (Week 1), Post-Treatment (Week 10), 3 months follow-up postpartum)
  • Changes in measures of heart rate variability from baseline to 3 months(Baseline (Week 1), Post-Treatment (Week 10), 3 months follow-up postpartum)
  • Change in Pregnancy Related Anxiety Measure scores from baseline to post-treatment(Baseline (Week 1), Post-Treatment (Week 10))

Study Sites (2)

Loading locations...

Similar Trials